Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTSR2 | O95665 | 3/20 | 0.54 |
| ▸ | NTSR1 | P30989 | 3/20 | 0.54 |
| ▸ | F2 | P00734 | 2/20 | 0.51 |
| ▸ | NPY4R | P50391 | 5/20 | 0.49 |
| ▸ | NPY1R | P25929 | 4/20 | 0.49 |
| ▸ | NPY2R | P49146 | 4/20 | 0.49 |
| ▸ | NPY5R | Q15761 | 4/20 | 0.49 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.49 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.49 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.49 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.49 |
| ▸ | KISS1R | Q969F8 | 2/20 | 0.48 |
| ▸ | SORT1 | Q99523 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29974534 | 1.00 | NTSR2 (0.54) | NTSR2NTSR1F2NPY4RNPY1R | |
| SCHEMBL29973963 | 0.91 | F2 (0.52) | NTSR2NTSR1F2KISS1R | |
| SCHEMBL29974829 | 0.91 | F2 (0.52) | NTSR2NTSR1F2KISS1R | |
| SCHEMBL8894047 | 0.90 | VIPR2 (0.52) | F2OPRD1KISS1R | |
| SCHEMBL29611448 | 0.89 | BACE1 (0.56) | F2NPY4RNPY1RNPY2RNPY5R | |
| SCHEMBL30798852 | 0.88 | F2 (0.49) | NTSR2NTSR1F2NPY4RNPY1R | |
| SCHEMBL30239118 | 0.87 | BACE1 (0.55) | NTSR2NTSR1F2 | |
| SCHEMBL8894659 | 0.87 | VIPR2 (0.56) | F2KISS1R | |
| SCHEMBL8894994 | 0.86 | KISS1R (0.59) | OPRM1OPRD1OPRK1KISS1R | |
| SCHEMBL30798736 | 0.86 | F2 (0.53) | NTSR2NTSR1F2NPY4RNPY1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230399361-A1 | MACROCYCLIC PEPTIDES | UNIVERSITY OF NOTRE DAME DU LAC | 2023-12-14 | — | — | US | claimed |
| US-20240116984-A1 | MODIFIED PEPTIDES FOR THE INHIBITION OF ABNORMAL TAU ACCUMULATION | NATIONAL SCIENCE FOUNDATION | 2024-04-11 | — | — | US | disclosed |
| EP-4329791-A1 | MODIFIED PEPTIDES FOR THE INHIBITION OF ABNORMAL TAU ACCUMULATION | University of Notre Dame du Lac (US) | 2024-03-06 | — | — | EP | disclosed |
| US-20230399361-A1 | MACROCYCLIC PEPTIDES | UNIVERSITY OF NOTRE DAME DU LAC | 2023-12-14 | — | — | US | disclosed |
| WO-2022232007-A1 | MODIFIED PEPTIDES FOR THE INHIBITION OF ABNORMAL TAU ACCUMULATION | UNIVERSITY OF NOTRE DAME DU LAC (US) | 2022-11-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240116984-A1 | MODIFIED PEPTIDES FOR THE INHIBITION OF ABNORMAL TAU ACCUMULATION | PRNP, MAPT, APP | NTSR2 1511/4885NTSR1 1640/4885F2 3097/4885 |
| US-20230399361-A1 | MACROCYCLIC PEPTIDES | APP, MAPT, NEFM | NTSR2 286/4885NTSR1 370/4885F2 1594/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.